Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
People with active cancer or history of cancer within 5 years should avoid use because growth factors and angiogenesis promotion could theoretically affect tumor growth
Mechanism difference Semaglutide (GLP-1 agonist): appetite regulation, satiety, improved glycemic control (New England Journal of Medicine) Tirzepatide (GLP-1/GIP agonist): broader incretin effects, robust appetite/weight effects (New England Journal of Medicine) AOD-9604: targeted fat-metabolism signaling
The combination of these two peptides engages non-overlapping cellular axes
The price gap between $49 research peptide and $445 medical protocol is not arbitrary
US$ 21.71
US$ 25.20
US$ 24.58
US$ 24.11
US$ 23.56
